Nov 5, 2025 7:05 am EST Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain
Nov 5, 2025 7:00 am EST Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025
Oct 6, 2025 7:00 am EDT Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
Sep 19, 2025 7:00 am EDT Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
Sep 4, 2025 7:00 am EDT Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
Aug 27, 2025 7:00 am EDT Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
Aug 21, 2025 7:00 am EDT Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
Aug 7, 2025 4:01 pm EDT Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
Jul 30, 2025 7:00 am EDT Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025